---
title: "Pierre-Olivier Ally"
id: "612"
type: "collaborateur"
slug: "pierre-olivier-ally"
published_at: "2025-12-29T09:26:16+00:00"
modified_at: "2026-09-02T12:29:09+00:00"
url: "https://www.august-debouzy.com/en/collaborateur/pierre-olivier-ally/"
markdown_url: "https://www.august-debouzy.com/en/collaborateur/pierre-olivier-ally.md"
taxonomy_language:
  - "English"
taxonomy_post_translations:
  - "pll_69524938dca42"
taxonomy_tax_expertise:
  - "Digital Assets"
  - "Patent Litigation"
  - "Patents"
taxonomy_tax_fonction:
  - "Counsel"
taxonomy_tax_langue:
  - "English"
  - "French"
taxonomy_tax_localisation:
  - "Paris"
---

[Profil Linkedin](https://www.linkedin.com/in/pierreolivierally/)

[Voir la page Équipe](https://www.august-debouzy.com/en/team/)

# Pierre-Olivier Ally

- Position Counsel
- Email poally@august-debouzy.com
- Phone Number +33145618329
- Languages English, French
- Location Paris
- Bar Paris Bar, New York Bar, Québec Bar

## Practice Areas

- [Digital Assets](https://www.august-debouzy.com/en/expertise/digital-assets/)
- [Patent Litigation](https://www.august-debouzy.com/en/expertise/patent-litigation/)
- [Patents](https://www.august-debouzy.com/en/expertise/patents/)

0

## Biography

Pierre-Olivier Ally joined August Debouzy in 2021. He focuses on intellectual property law, particularly in national and international patent litigation.

He brings extensive experience in drafting and negotiating patent and know-how licenses and software agreements and addressing open source issues. Additionally, Pierre-Olivier assists our clients with the intellectual property aspects of mergers and acquisitions, financing, IPOs, joint ventures and public and/or private R&D contracts.

Before joining August Debouzy, he spent most of his career at leading international law firms in Paris and later served as the Chief IP Counsel for a European tech unicorn in Amsterdam.

> Lionel Martin and Pierre-Olivier Ally are part of the new talented and creative guard that will make waves in the years to come. Superstars.
> 
>  Legal 500 2025

## Background

- 2009 UdeM | J.D.
- 2009 UdeM | LL.B.
- 2006 McGill | B.Sc. (Chimie)

## *Rankings and* **Recognition**

m

- (01)Best Lawyers 2027 - France Technologies Media IP The Best Lawyers in France
- (02)IAM 2026 - France Transactions Recommended
- (03)Juve Patent 2026 - Global Ones to Watch in litigation

[More distinctions](https://www.august-debouzy.com/en/distinctions/?search_type-collaborateur%5B%5D=pierre-olivier-ally)

## *Latest* News

k

[18/06/26 Press release 1 min August Debouzy Establishes Dedicated Crypto-Assets and Blockchain Offering](https://www.august-debouzy.com/en/press-release/august-debouzy-establishes-dedicated-crypto-assets-and-blockchain-offering/)

[06/02/26 Legal Article 1 min No commitment, no certificate: loose combinations and the SPC regulation The article examines the continued ineligibility of “loose combinations” for SPC protection, a position confirmed by recent decisions in France, the UK and Germany. As the upcoming EU reform does not address this gap, pharmaceutical companies need to anticipate these IP and regulatory challenges when developing combination therapies.](https://www.august-debouzy.com/en/legal-article/no-commitment-no-certificate-loose-combinations-and-the-spc-regulation/)

[10/09/25 Legal Article 10 min UPC Court of Appeal Clarifies Standards for Imminent Infringement in Pharmaceutical Patent Disputes The UPC Court of Appeal clarifies imminent infringement in pharma cases, overturning Boehringer v. Zentiva ruling and aligning with EU case law.](https://www.august-debouzy.com/en/legal-article/upc-court-of-appeal-clarifies-standards-for-imminent-infringement-in-pharmaceutical-patent-disputes/)

[28/05/25 Legal Article 4 min The LD Lisbon Offers Some Limited Insight on Imminent Threat of Infringement On 8 May 2025, the Lisbon Local Division of the Unified Patent Court (“UPC”) issued an order (Boehringer Ingelheim International GmbH v. Zentiva Portugal LDA, Lisbon LD, 8 May 2025, UPC_CFI_41/2025) denying a preliminary injunction application filed by Boehringer Ingelheim International GmbH (“Boehringer”) against Zentiva Portugal LDA (“Zentiva”).](https://www.august-debouzy.com/en/legal-article/the-ld-lisbon-offers-some-limited-insight-on-imminent-threat-of-infringement/)

[16/05/25 Legal Article 7 min First Unified Patent Court Ruling on Second Medical Use Claims On 13 May 2025, the Düsseldorf Local Division of the Unified Patent Court issued a landmark decision on the merits relating to a second medical use claim (Sanofi Biotechnology SAS and Regeneron Pharmaceuticals Inc. v. Amgen Inc. et al., 13 May 2025, UPC_CFI_505/2024). The decision follows an infringement action brought by Regeneron and Sanofi, respectively the proprietor and exclusive licensee of European Patent No 3 536 712 ("EP’712"), against various…](https://www.august-debouzy.com/en/legal-article/first-unified-patent-court-ruling-on-second-medical-use-claims/)

01

05

Précédent     Suivant

[Explore Our News](https://www.august-debouzy.com/en/le-hub-list/)
k

News